Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Public Health

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

The impact of drug use patterns on mortality among polysubstance users in a Canadian setting: a prospective cohort study

  • Anna Hayden1,
  • Kanna Hayashi1,
  • Huiru Dong1,
  • Michael-John Milloy1, 2,
  • Thomas Kerr1, 2,
  • Julio SG Montaner1, 2 and
  • Evan Wood1, 2Email author
BMC Public Health201414:1153

https://doi.org/10.1186/1471-2458-14-1153

Received: 8 May 2014

Accepted: 9 October 2014

Published: 6 November 2014

Abstract

Background

Illicit drug use is a well-established risk factor for morbidity and mortality. However, few studies have examined the impact of different drug use patterns on mortality among polysubstance using populations. This study aimed to identify drug-specific patterns of mortality among a cohort of polysubstance using persons who inject drugs (PWIDs).

Methods

PWIDs in Vancouver, Canada were prospectively followed between May 1996 and December 2011. Participants were linked to the provincial vital statistics database to ascertain mortality rates and causes of death. We used multivariate Cox proportional hazards regression to investigate the relationships between drug use patterns (daily alcohol use, heroin injection and non-injection use, cocaine injection, amphetamine injection and non-injection use, crack smoking and speedball injecting) and time to all-cause mortality.

Results

2330 individuals were followed for a median of 61 months (inter-quartile range: 33 – 112). In total, 466 (19.1%) individuals died for an incidence density of 3.1 (95% confidence interval [CI]: 2.8 – 3.4) deaths per 100 person-years. In multivariate analyses, after adjusting for HIV infection and other potential confounders, only daily cocaine injection remained independently associated with all-cause mortality (adjusted hazard ratio [AHR] = 1.36, 95% CI: 1.06 – 1.76).

Conclusions

Although heroin injecting is traditionally viewed as carrying the highest risk of mortality, in this setting, only daily cocaine injecting was associated with all-cause mortality. These findings highlight the urgent need to identify novel treatments and harm reduction strategies for cocaine injectors.

Keywords

MortalityInjection drug useCocaineVancouverCohort study

Background

Illicit drug use has been well established as a risk factor for adverse health outcomes including premature mortality [16]. Previous studies have indicated that fatal overdose accounts for a majority of deaths in illicit drug-using populations, particularly among persons who inject drugs (PWIDs) [35, 7, 8]. Much of the existing literature has highlighted opioid use associated with fatal overdose [1, 7, 9, 10]. One meta-analysis found that illicit opiate users have a mortality rate thirteen times that of the general population [1]. An increased mortality rate has also been demonstrated among users of other substances, including cocaine and amphetamines [4, 6, 11, 12].

Earlier studies of mortality among PWIDs have often been limited by the fact that they were restricted to cross-sectional examinations of toxicology reports among deceased individuals where important potential confounders, such as human immunodeficiency virus (HIV) infection or other socio-demographic comorbidities, like homelessness, were difficult to control for [2, 7, 13, 14]. While longstanding prospective cohort studies of PWIDs exist in a number of regions, some of which have adjusted for potential confounders, many have been undertaken in areas where a limited number of specific drugs are primarily used (e.g. primarily heroin or cocaine users) [7, 10, 11, 1517].

The Downtown Eastside of Vancouver (DTES), Canada is well known for its concentration of poly-substance use, high prevalence of hepatitis C virus (HCV) and HIV infection and high rates of homelessness [18, 19]. The DTES is among the most impoverished neighborhoods in Canada with an estimated 5000 PWIDs residing in the area [18, 19]. Various patterns of drug use in this population have been described in previous studies including high rates of cocaine injecting [20], crack cocaine smoking [21], amphetamine injecting [22] and heroin injecting [23]. Accordingly, it provides an excellent environment to examine the contribution of specific drug use patterns on mortality. Therefore, the present study aimed to identify drug specific patterns of mortality among a cohort of polysubstance using PWIDs in Vancouver.

Methods

The Vancouver Injection Drug Users Study (VIDUS) and AIDS Care Cohort to Evaluate Access to Survival Services (ACCESS) are open prospective cohorts of drug users in Vancouver. The recruitment and follow-up procedures for the two studies are identical to allow for analyses of merged data, with the only differences being that HIV-positive individuals are followed in ACCESS whereas HIV-negative individuals are followed in VIDUS and that ACCESS includes non-injecting drug users. In both studies the primary modes of enrollment were self-referral, word of mouth, and street outreach. Detailed sampling and recruitment procedures for these two cohorts have been described elsewhere [20, 24, 25].

To be eligible, participants were 18 years of age or older, had used illicit drugs other than cannabinoids in the previous month and resided in the greater Vancouver region. All participants provided written informed consent. Participants were given a stipend ($20 CDN) at each study visit for their time and transportation. The study was approved by the University of British Columbia/Providence Healthcare Research Ethics Board.

At baseline and semianually thereafter, participants completed an interviewer-administered questionnaire that elicited a range of data, including demographic characteristics, injection and non-injection drug use, and sexual risk behaviors. In addition, venous blood samples were drawn at each visit and tested for HIV and HCV antibodies. All participants had private interviews and were offered both pre- and post-test counseling with trained nurses. Referral for free healthcare was provided to those who tested HIV positive and these individuals were subsequently followed in ACCESS.

We ascertained all-cause mortality rates and underlying causes of death among participants through a confidential record linkage with the British Columbia Vital Statistics Agency and through ongoing follow-up with contacts provided by participants. The Vital Statistics database recorded causes of death according to the International Classification of Diseases (ICD), 10th edition.

The present study included PWIDs who were recruited and completed at least one follow up visit between May 1996 and December 2011. To avoid potential bias relating to long durations between the last study visit where behavioural information was assessed and the date of death (i.e. loss to regular follow up), individuals who were identified as deceased more than 12 months after the the last follow up visit were censored on the date of the last follow up.

The primary endpoint in this analysis was all-cause mortality. The primary explanatory variables of interest included a number of substance use behaviors in the previous six months, including at least daily alcohol use, at least daily cocaine injection, at least daily heroin injection and non-injection use, at least daily amphetamine injection and non-injection use, at least daily crack cocaine smoking and at least daily speedball injecting (a mixture of cocaine and heroin). Additionally, we examined risk associated with non-daily heroin and amphetamine use defined as any report of use in the last six months. Potential confounders that were considered included: age (per 10 years older); gender (male vs. female), time since first injection (per 10 years longer); ethnicity (Caucasian vs. others); HIV serostatus (positive vs. negative); and unstable housing in the previous six months. As previously, unstable housing was defined as living in one of the DTES’ single room occupancy hotels, shelters or other transitional housing, or living on the street [26, 27].

As an initial analysis, we used the Chi-square test and Wilcoxon rank sum test to compare the baseline characteristics of the included and excluded individuals, and those who did and did not report daily cocaine injection in the previous six months among the included sample based on an interest in the role of cocaine injecting on mortality. All-cause mortality rate and 95% confidence interval [CI] were calculated using the Poisson distribution.

Next, we used bivariate and multivariate Cox proportional hazards regression to examine the relationship between substance use patterns and time to death. All behavioral variables including substance use patterns, unstable housing and HIV serostatus were treated as time-varying variables. The multivariate model was fit using an a priori defined protocol whereby all illicit drug use variables were entered into the multivariate model. Variables found to be significantly associated with time to all-cause mortality in bivariate analyses at p <0.10 were entered into the multivariate model as potential confounders.

We also conducted a sub-analysis where we restricted the dependent variable to accidental poisonings (ICD-10: X40–44) and other accidental causes of death to specifically examine if drug use patterns were associated with accidental death. All statistical analyses were performed using SAS software version 9.3 (SAS, Cary, NC). All p-values were two-sided.

Results

A total of 2597 individuals were recruited between May 1996 and December 2011, among whom 267 were excluded as a result of no follow-up information. In comparing the study sample to those that were excluded, the excluded sample was younger, less likely to be HIV positive and was less likely to inject cocaine and speed ball (all p <0.05).

The remaining 2330 (89.7%) were followed for a median of 61 months (inter-quartile range [IQR]: 33 – 112). Table 1 shows the baseline characteristics of the study sample. As shown, at baseline, 1550 (66.5%) were men, 640 (27.5%) were HIV positive, and 1424 (61.1%) were Caucasian. The median age was 37.3 years (IQR: 29.4 – 43.7), and the median time since first injection was 14.4 years (IQR: 6.2 – 24.2). At baseline, 550 (23.6%) of the study sample consumed alcohol daily in the previous six months, 901 (38.7%) injected heroin daily, 97 (4.2%) smoked heroin daily, 1588 (68.2%) injected cocaine daily, 51 (2.2%) injected amphetamines daily, 7 (0.3%) smoked amphetamines daily, 560 (24.0%) smoked crack cocaine daily, and. 288 (12.4%) injected speedball daily.
Table 1

Baseline demographics of the study population stratified by daily cocaine injection in the past 6 months (n = 2330)

Characteristic

Total (%)

Daily cocaine injection

  
  

Yes (%)

No (%)

Odds ratio (95% CI)

p value

 

(n = 2330)

(n = 1588)

(n = 728)

  

HIV serostatus

     

 Positive

640 (27.5)

212 (29.1)

426 (26.8)

1.12 (0.92 – 1.36)

0.247

 Negative

1688 (72.5)

515 (70.7)

1161 (73.1)

  

Gender

     

 Male

1550 (66.5)

444 (61.0)

1098 (69.1)

0.70 (0.58 – 0.84)

<0.001

 Female

780 (33.5)

284 (39.0)

490 (30.9)

  

Ethnicity

     

 Caucasian

1424 (61.1)

413 (56.7)

1001 (63.0)

0.77 (0.64 – 0.92)

0.004

 Other

906 (38.9)

315 (43.3)

587 (37.0)

  

Unstable housing*

     

 Yes

1637 (70.3)

556 (76.4)

1072 (67.5)

1.62 (1.32 – 1.99)

<0.001

 No

677 (29.1)

163 (22.4)

509 (32.1)

  

Median age (IQR)

     

 Per 10 year older

37.3 (14.3)

35.3 (13.4)

38.4 (14.1)

0.76 (0.69 – 0.83)

<0.001

Median time since first injection (IQR)

     

 Per 10 year longer

14.4 (18.0)

14.1 (16.3)

14.6 (18.8)

0.91 (0.84 – 0.99)

0.033

Daily alcohol use*

     

 Yes

550 (23.6)

179 (24.6)

368 (23.2)

1.10 (0.88 – 1.33)

0.450

 No

1775 (76.2)

547 (75.1)

1217 (76.6)

  

Daily heroin injection*

     

 Yes

901 (38.7)

345 (47.4)

555 (35.0)

1.68 (1.40 – 2.00)

<0.001

 No

1424 (61.1)

383 (52.6)

1033 (65.1)

  

Daily heroin (non-injection)*

     

 Yes

97 (4.2)

30 (4.1)

66 (4.2)

0.99 (0.64 – 1.54)

0.969

 No

2230 (95.7)

697 (95.7)

1520 (95.7)

  

Daily amphetamine injection*

     

 Yes

51 (2.2)

7 (1.0)

44 (2.8)

0.34 (0.15 – 0.76)

0.006

 No

2274 (97.6)

721 (99.0)

1542 (97.1)

  

Daily amphetamine (non-injection)*

     

 Yes

7 (0.3)

1 (0.1)

6 (0.4)

0.36 (0.04 – 3.02)

0.445

 

2322 (99.7)

727 (99.9)

1581 (99.6)

  

Daily crack cocaine smoking*

     

 Yes

560 (24.0)

137 (18.8)

420 (26.5)

0.65 (0.52 – 0.80)

<0.001

 No

1767 (75.8)

589 (80.9)

1167 (73.5)

  

Daily speedball injection*

     

 Yes

288 (12.4)

216 (29.7)

71 (4.5)

9.01 (6.77 – 12.00)

<0.001

 No

2038 (87.5)

512 (70.3)

1516 (95.5)

  

*Refers to activities in the six months prior to interview. IQR = Interquartile range. Fisher’s Exact Test.

Compared to non-daily cocaine injectors, those who reported daily cocaine injection at baseline were more likely to be younger (odds ratio [OR] = 0.76, 95% CI: 0.69 – 0.83), to reside in unstable housing (OR = 1.62, 95% CI: 1.32 – 1.99), and to have less time since first injection (OR = 0.91, 95% CI: 0.84 – 0.99). They were less likely to be male (OR = 0.70, 95% CI: 0.58 – 0.84) and report Caucasian ethnicity (OR = 0.77, 95% CI: 0.64 – 0.92). In terms of drug use patterns, daily cocaine injection was significantly and positively associated with daily heroin injection (OR = 1.68, 95% CI: 1.40 – 2.00) and speedball injection (OR = 9.01, 95% CI 6.77 – 12.00), and negatively associated with daily amphetamine injection (OR = 0.34, 95% CI: 0.15 – 0.76), and daily crack smoking (OR = 0.65, 95% CI: 0.52 – 0.80).

In total, 466 (19.1%) individuals died for an incidence density of 3.1 (95% CI: 2.8 – 3.4) deaths per 100 person-years. The primary underlying causes of death included accidental poisonings (22.6%) and HIV disease (18.5%). The remaining 100 classified categories including assault (2.3%) and lung malignancy (2.4%) are varied and each individually contributed less than 5%, with most contributing less than 1% to all-cause mortality.

Table 2 shows results of the bivariate and multivariate Cox regression analyses of all-cause mortality. In the bivariate analysis, daily cocaine injection was significantly and positively associated with time to all-cause mortality with a hazard ratio (HR) of 1.41 (95% CI: 1.12 – 1.78) whereas daily heroin injection was significantly and negatively associated with the ouctome with a HR of 0.75 (95% CI: 0.60 – 0.95). Daily alcohol use (HR = 0.98, 95% CI: 0.77 – 1.25), daily heroin non-injection use (HR = 1.12, 95% CI: 0.51 – 2.44), amphetamine injection (HR = 0.39, 95% CI: 0.10 – 1.54) and non-injection use (HR = 1.13, 95% CI: 0.29 – 4.50), daily crack cocaine smoking (HR = 0.91, 95% CI: 0.74 – 1.12) and daily speedball injection (HR = 1.02, 95% CI: 0.69 – 1.52) were not significantly associated with time to all-cause mortality. A bivariate analysis of non-daily heroin use (HR = 0.99, 95% CI: 0.72 -1.37) and amphetamine (HR = 0.47, 95% CI: 0.23 – 1.02) use, which was not included in the tables showed no significant association with mortality.
Table 2

Univariate and multivariate Cox proportional hazard regression analyses of the time to all-cause death among people who inject drugs in Vancouver, Canada (n = 2330)

 

Unadjusted hazard ratio (HR)

Adjustedhazard ratio (AHR)

Variable

HR

(95% CI)

p -value

AHR

(95% CI)

p -value

Daily alcohol use*

0.98

0.77 – 1.25

0.854

1.00

0.78 – 1.28

0.979

Daily heroin injection*

0.75

0.60 – 0.95

0.018

0.92

0.71 – 1.19

0.502

Daily heroin (non-injection)*

1.12

0.51 – 2.44

0.779

1.44

0.68 – 3.07

0.340

Daily cocaine injection*

1.41

1.12 – 1.78

0.003

1.36

1.06 – 1.76

0.017

Daily amphetamine injection*

0.39

0.10 – 1.54

0.177

0.41

0.10 – 1.72

0.224

Daily amphetamine (non-injection)*

1.13

0.29 – 4.50

0.859

0.94

0.13 – 6.88

0.949

Daily crack cocaine smoking*

0.91

0.74 – 1.12

0.358

0.83

0.67 – 1.04

0.099

Daily speedball injectionn

1.02

0.69 – 1.52

0.917

0.98

0.62 – 1.56

0.944

*Refers to activities in the six months prior to interview. Model was adjusted for HIV serostatus, age, and unstable housing.

In the multivariate analysis, after adjustment for potential confounders including HIV serostatus, age and unstable housing, daily cocaine injection remained independently and positively associated with time to all-cause death (adjusted hazard ratio [AHR] = 1.36, 95% CI: 1.06 – 1.76) whereas the remaining substance use variables were not significantly associated with the outcome.

The sub-analysis whereby the dependent variable was restricted to accidental mortality showed that none of the substance use variables was significantly associated with accidental mortality. The only variable where there was a trend towards an association with accidental mortality was daily crack cocaine injecting, though this was not statistically significant (AHR = 1.36, 95% CI: 0.91– 2.10). Full data are available from the corresponding author.

Discussion

In the present study, we found that daily cocaine injection was independently associated with all-cause mortality among PWIDs in Vancouver, after adjusting for potential confounders including age, unstable housing and HIV serostatus. These variables are known risk factors for mortality and were included in the analysis in order to adjust for their potential confounding effects [8]. The most common causes of death included accidental poisonings and HIV disease. We did not observe an independent mortality risk associated with daily alcohol use, daily heroin injection or non-injection use, daily amphetamine injection or non-injection use, daily crack cocaine smoking and daily speedball injecting.

Our findings that daily cocaine injection was the only drug use behaviour independently associated with mortality were somewhat unique in the context of previous literature indicating a significant mortality risk associated with heroin injection most commonly due to fatal overdose [5]. Heroin use has been shown to carry the highest mortality risk amongst illicit drugs in some studies [14, 28, 29]. Particularly, non-daily heroin use is thought to carry mortality risk due to diminished tolerance to respiratory depression effects with sporadic use leading to increased of accidental overdose [30]. However, our analysis showed no significant increase in mortality risk in both daily and non-daily heroin users. While the underlying reasons for the discrepancy between these previous studies and our study findings are not entirely clear, a contributing factor may be related to frequency of drug injecting, which was not accounted for in the previous studies [4, 8]. Due to the short half life of cocaine, injectors will often use greater than 20 times in a day, predisposing them to increased risk of infection/bacteremia and other associated negative health effects, while local heroin injectors typically inject only 2 to 4 times per day [20]. Rates of injecting may increase risk of bacterial infection, needle sharing and other potential risks of mortality (e.g. air embolus, cellulitis, etc.) [12, 20, 28].

We also found a differential risk of mortality between cocaine injectors and crack smokers. Some cohort studies have demonstrated an independent mortality risk associated with cocaine use [4, 12] in addition to significant morbidity associated with the use of this substance, including cardiovascular, psychiatric, neurologic disorders and unintentional injuries [16]. Much of the mortality data on cocaine use however does not distinguish between injecting and smoking crack cocaine [16, 17, 28]. Furthermore, the majority of these studies present data in standardized mortality ratios, which allow for a comparison with the general population but not between sub-groups of cocaine-using populations, as performed in the present study. Though both cocaine injection and crack smoking have been shown to be associated with HIV infection in this setting [20, 31], our multivariate analyses suggest that daily cocaine injectors appear to be at an elevated risk of mortality due to the risks associated with injection practices other than HIV infection.

Harm reduction strategies, including a supervised injecting facility, in Vancouver’s DTES have been shown to be successful at attracting cocaine injectors, reducing rates of fatal overdose [32, 33] and reducing syringe sharing and HIV risk behavior [34, 35] among the local PWID population. It is noteworthy that both cocaine and heroin injectors utilize this unique program, [35] which is widely accessible for extended hours. It also connects PWIDs to addiction services, contributing to quicker entry into detoxification programs [36] and leading to increased likelihood of stopping drug injecting [37].

The findings of this study highlight a need to further identify addiction treatment and public health strategies tailored for cocaine injectors. Currently, there is no standard pharmacotherapy proven effective for cocaine addiction, though multiple therapeutic agents, including anticonvulsants and stimulants have been investigated as potential treatments [38, 39]. A recent comprehensive review of human clinical trials for potential novel therapies for treatment of cocaine dependence outlined burgeoning research in this field. It identified multiple promising pharmocotherapies including dopamine agonists, serotonergic agents and GABA-ergic medications and a cocaine vaccine. One promising randomized controlled trial from 2013 demonstrated that topiramate was more efficacious than placebo at reducing weekly cocaine use [40]. Additionally, contingency management strategies have been presented as possible interventions. One such study showed that employment-based abstinence reinforcement could lead to increased cocaine abstinence [41]. However, these strategies have been found to be challenging to implement [38]. Future research should continue to seek to identify a novel therapeutic intervention model to reduce morbidity and mortality among cocaine injectors in this setting.

A recent systematic review of mortality among PWIDs found no significant differences in the risk of death by type of primary drug injected [8]. The authors noted some factors that reduced their capacity to detect such differences, including a lack of adjustment for poly-substance use, changes in participants’ drug use habits that may not have been accounted for, and the fact that HIV status was often imprecisely measured [8]. Another systematic review of mortality among cocaine users noted limited data on the extent of elevated mortality among cocaine users [4]. They highlighted limitations of previous studies, including the fact that many cohorts were formed in drug treatment facilities with dependent cocaine users who were at increased risk of premature death and that the prevalence of HIV infection between studies was highly variable [4]. Our study addressed some of the limitations of previous studies by accounting for poly-substance use, following up with participants semi-annually to monitor ongoing drug use habits, and testing for HIV infection at each visit. Furthermore, unlike many previous studies, the present study population was not selected from a drug treatment facility or comprised of cross-sectional examinations of deceased individual’s toxicology reports.

There are several limitations in this study. Firstly, the study sample is not a random sample, and therefore generalizability of our findings may be limited. Secondly, much of the data, particularly regarding drug use patterns, were ascertained through self–reporting. Therefore, our data may have been affected by reporting biases including recall bias and socially desirable reporting. However, we note that this type of data has been commonly utilized in observational studies involving PWIDs and found to be valid [42, 43]. Third, drug use patterns directly before or at the time of death are not described due to the method of self-reporting, which inhibits our ability to ascertain data as proximal to the time of death. Fourth, although migration rates out of the province have been shown to be low, mortality rates may be underestimated, as participants who died outside of BC were not included in the provincial registry. We censored individuals with long durations (>12 months) from behavioural measurement to death on the date of last behavioural measurement. This may have resulted in loss of precision regarding our risk factor measurement. Fifth, for many variables, including alcohol use, we did not have measures that considered refined patterns of use or frequency of use and were often dichotomized into daily versus less than daily use. Lastly, when the endpoint was restricted to accidental mortality, daily cocaine injecting did not remain significantly associated with the time to accidental death, despite a trend towards an association. This may reflect that accidental deaths, including accidental poisonings, assault and accidental falls, are not necessarily predicted by specific drug use patterns. Future research should seek to identify predictors of accidental mortality among PWID. Finally, certain patterns of drug use, such as intranasal cocaine use, are uncommon in this sample and were not measured in our study.

Conclusions

In summary, daily cocaine injecting was the only drug use pattern independently associated with all-cause mortality among a sample of PWIDs in Vancouver. These findings highlight the need to identify novel effective treatments and harm reduction strategies for cocaine injectors.

Abbreviations

AHR: 

Adjusted hazard ratio

ACCESS: 

AIDS Care Cohort to Evaluate Access to Survival Services

CI: 

Confidence interval

DTES: 

Downtown Eastside

HCV: 

Hepatitis C virus

HIV: 

Human immunodeficiency virus

PWIDs: 

Persons who inject drugs

VIDUS: 

Vancouver Injection Drug Users Study.

Declarations

Acknowledgements

The authors thank the study participants for their contribution to the research, as well as current and past researchers and staff. The study was supported by the US National Institutes of Health (VIDUS: R01DA011591, ACCESS: R01DA021525). This research was undertaken, in part, thanks to funding from the Canada Research Chairs program through a Tier 1 Canada Research Chair in Inner City Medicine which supports Dr. Wood. Dr. Milloy is supported by the Canadian Institutes of Health Research and the Michael Smith Foundation for Health Research. Dr. Montaner is supported by the British Columbia Ministry of Health and by the US National Institutes of Health (R01DA036307). He has also received limited unrestricted funding from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV Healthcare.

Authors’ Affiliations

(1)
British Columbia Centre for Excellence in HIV/AIDS, St. Paul’s Hospital
(2)
Department of Medicine, University of British Columbia

References

  1. Hulse GK, English DR, Milne E, Holman CD: The quantification of mortality resulting from the regular use of illicit opiates. Addiction. 1999, 94 (2): 221-229. 10.1046/j.1360-0443.1999.9422216.x.View ArticlePubMedGoogle Scholar
  2. Coffin PO, Galea S, Ahern J, Leon AC, Vlahov D, Tardiff K: Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990–98. Addiction. 2003, 98 (6): 739-747. 10.1046/j.1360-0443.2003.00376.x.View ArticlePubMedGoogle Scholar
  3. Stoove MA, Dietze PM, Aitken CK, Jolley D: Mortality among injecting drug users in Melbourne: a 16-year follow-up of the Victorian Injecting Cohort Study (VICS). Drug Alcohol Depend. 2008, 96 (3): 281-285. 10.1016/j.drugalcdep.2008.03.006.View ArticlePubMedGoogle Scholar
  4. Degenhardt L, Singleton J, Calabria B, McLaren J, Kerr T, Mehta S, Kirk G, Hall WD: Mortality among cocaine users: a systematic review of cohort studies. Drug Alcohol Depend. 2011, 113 (2–3): 88-95.View ArticlePubMedGoogle Scholar
  5. Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren J: Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011, 106 (1): 32-51. 10.1111/j.1360-0443.2010.03140.x.View ArticlePubMedGoogle Scholar
  6. Singleton J, Degenhardt L, Hall W, Zabransky T: Mortality among amphetamine users: a systematic review of cohort studies. Drug Alcohol Depend. 2009, 105 (1–2): 1-8.View ArticlePubMedGoogle Scholar
  7. Davidson PJ, McLean RL, Kral AH, Gleghorn AA, Edlin BR, Moss AR: Fatal heroin-related overdose in San Francisco, 1997–2000: a case for targeted intervention. J Urban Health. 2003, 80 (2): 261-273. 10.1093/jurban/jtg029.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M: Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013, 91 (2): 102-123. 10.2471/BLT.12.108282.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Warner-Smith M, Darke S, Day C: Morbidity associated with non-fatal heroin overdose. Addiction. 2002, 97 (8): 963-967. 10.1046/j.1360-0443.2002.00132.x.View ArticlePubMedGoogle Scholar
  10. Hickman M, Carnwath Z, Madden P, Farrell M, Rooney C, Ashcroft R, Judd A, Stimson G: Drug-related mortality and fatal overdose risk: pilot cohort study of heroin users recruited from specialist drug treatment sites in London. J Urban Health. 2003, 80 (2): 274-287. 10.1093/jurban/jtg030.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Arendt M, Munk-Jorgensen P, Sher L, Jensen SO: Mortality following treatment for cannabis use disorders: predictors and causes. J Subst Abuse Treat. 2013, 44 (4): 400-406. 10.1016/j.jsat.2012.09.007.View ArticlePubMedGoogle Scholar
  12. Tyndall MW, Craib KJ, Currie S, Li K, O’Shaughnessy MV, Schechter MT: Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr. 2001, 28 (4): 351-357. 10.1097/00126334-200112010-00008.View ArticlePubMedGoogle Scholar
  13. Merrall EL, Bird SM, Hutchinson SJ: Mortality of those who attended drug services in Scotland 1996–2006: record-linkage study. Int J Drug Policy. 2012, 23 (1): 24-32. 10.1016/j.drugpo.2011.05.010.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Bartu A, Freeman NC, Gawthorne GS, Codde JP, Holman CD: Mortality in a cohort of opiate and amphetamine users in Perth, Western Australia. Addiction. 2004, 99 (1): 53-60. 10.1111/j.1360-0443.2004.00602.x.View ArticlePubMedGoogle Scholar
  15. Kaye S, Darke S: Non-fatal cocaine overdose among injecting and non-injecting cocaine users in Sydney, Australia. Addiction. 2004, 99 (10): 1315-1322. 10.1111/j.1360-0443.2004.00875.x.View ArticlePubMedGoogle Scholar
  16. Barrio G, Molist G, de la Fuente L, Fernandez F, Guitart A, Bravo MJ, Brugal MT: Mortality in a cohort of young primary cocaine users: controlling the effect of the riskiest drug-use behaviors. Addict Behav. 2013, 38 (3): 1601-1604. 10.1016/j.addbeh.2012.10.007.View ArticlePubMedGoogle Scholar
  17. Dias AC, Araujo MR, Dunn J, Sesso RC, de Castro V, Laranjeira R: Mortality rate among crack/cocaine-dependent patients: a 12-year prospective cohort study conducted in Brazil. J Subst Abuse Treat. 2011, 41 (3): 273-278. 10.1016/j.jsat.2011.03.008.View ArticlePubMedGoogle Scholar
  18. Maas B, Fairbairn N, Kerr T, Li K, Montaner JS, Wood E: Neighborhood and HIV infection among IDU: place of residence independently predicts HIV infection among a cohort of injection drug users. Health Place. 2007, 13 (2): 432-439. 10.1016/j.healthplace.2006.05.005.View ArticlePubMedGoogle Scholar
  19. Wood EKT: What do you do when you hit rock bottom? Responding to drugs in the city of Vancouver. Int J Drug Policy. 2006, 17 (2): 55-60. 10.1016/j.drugpo.2005.12.007.View ArticleGoogle Scholar
  20. Tyndall MW, Currie S, Spittal P, Li K, Wood E, O’Shaughnessy MV, Schechter MT: Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. Aids. 2003, 17 (6): 887-893. 10.1097/00002030-200304110-00014.View ArticlePubMedGoogle Scholar
  21. Werb D, Debeck K, Kerr T, Li K, Montaner J, Wood E: Modelling crack cocaine use trends over 10 years in a Canadian setting. Drug Alcohol Rev. 2010, 29 (3): 271-277. 10.1111/j.1465-3362.2009.00145.x.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Fairbairn N, Kerr T, Buxton JA, Li K, Montaner JS, Wood E: Increasing use and associated harms of crystal methamphetamine injection in a Canadian setting. Drug Alcohol Depend. 2007, 88 (2–3): 313-316.View ArticlePubMedGoogle Scholar
  23. Wood E, Montaner JS, Li K, Barney L, Tyndall MW, Kerr T: Rate of methadone use among Aboriginal opioid injection drug users. CMAJ. 2007, 177 (1): 37-40. 10.1503/cmaj.070105.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O’Shaughnessy MV, Montaner JS, Schechter MT, Hogg RS: Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998, 280 (6): 547-549. 10.1001/jama.280.6.547.View ArticlePubMedGoogle Scholar
  25. Milloy MJ, Kerr T, Buxton J, Rhodes T, Krusi A, Guillemi S, Hogg R, Montaner J, Wood E: Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2012, 59 (4): 393-399. 10.1097/QAI.0b013e3182433288.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Spittal PM, Craib KJ, Wood E, Laliberte N, Li K, Tyndall MW, O’Shaughnessy MV, Schechter MT: Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ. 2002, 166 (7): 894-899.PubMedPubMed CentralGoogle Scholar
  27. Craib KJ, Spittal PM, Wood E, Laliberte N, Hogg RS, Li K, Heath K, Tyndall MW, O’Shaughnessy MV, Schechter MT: Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ. 2003, 168 (1): 19-24.PubMedPubMed CentralGoogle Scholar
  28. Arendt M, Munk-Jorgensen P, Sher L, Jensen SO: Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: a nationwide follow-up study of Danish substance users in treatment. Drug Alcohol Depend. 2011, 114 (2–3): 134-139.PubMedGoogle Scholar
  29. Fugelstad A, Annell A, Rajs J, Agren G: Mortality and causes and manner of death among drug addicts in Stockholm during the period 1981–1992. Acta Psychiatr Scand. 1997, 96 (3): 169-175. 10.1111/j.1600-0447.1997.tb10147.x.View ArticlePubMedGoogle Scholar
  30. White JM, Irvine RJ: Mechanisms of fatal opioid overdose. Addiction. 1999, 94 (7): 961-972. 10.1046/j.1360-0443.1999.9479612.x.View ArticlePubMedGoogle Scholar
  31. DeBeck K, Kerr T, Li K, Fischer B, Buxton J, Montaner J, Wood E: Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. CMAJ. 2009, 181 (9): 585-589. 10.1503/cmaj.082054.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Marshall BD, Wood E: Putting risk compensation to rest: reframing the relationship between risk behavior and antiretroviral therapy among injection drug users. AIDS. 2012, 26 (18): 2405-2407. 10.1097/QAD.0b013e3283519b42.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T: Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011, 377 (9775): 1429-1437. 10.1016/S0140-6736(10)62353-7.View ArticlePubMedGoogle Scholar
  34. Kerr T, Tyndall M, Li K, Montaner J, Wood E: Safer injection facility use and syringe sharing in injection drug users. Lancet. 2005, 366 (9482): 316-318. 10.1016/S0140-6736(05)66475-6.View ArticlePubMedGoogle Scholar
  35. Wood E, Tyndall MW, Montaner JS, Kerr T: Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. CMAJ. 2006, 175 (11): 1399-1404. 10.1503/cmaj.060863.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Wood E, Tyndall MW, Zhang R, Stoltz JA, Lai C, Montaner JS, Kerr T: Attendance at supervised injecting facilities and use of detoxification services. N Engl J Med. 2006, 354 (23): 2512-2514. 10.1056/NEJMc052939.View ArticlePubMedGoogle Scholar
  37. Debeck KKT, Bird L, Zhang R, Marsh D, Tyndall M, Montaner J, Wood E: Injection drug use cessation and use of North America’s first medically supervised safer injecting facility. Drug Alcohol Depend. 2011, 113 (2–3): 172-176.View ArticlePubMedGoogle Scholar
  38. de Lima MS, de Oliveira Soares BG, Reisser AA, Farrell M: Pharmacological treatment of cocaine dependence: a systematic review. Addiction. 2002, 97 (8): 931-949. 10.1046/j.1360-0443.2002.00209.x.View ArticlePubMedGoogle Scholar
  39. Castells X, Casas M, Perez-Mana C, Roncero C, Vidal X, Capella D: Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2010, 2: CD007380Google Scholar
  40. Johnson BA-DN, Wang X, Penberthy K, Javors M, Seneviratne C: Topiramate for the treatment of cocaine addiction a randomized clinical trial. JAMA Psychiatry. 2013, 70 (12): 1338-1346. 10.1001/jamapsychiatry.2013.2295.View ArticlePubMedGoogle Scholar
  41. Silverman K, Wong CJ, Needham M, Diemer KN, Knealing T, Crone-Todd D, Fingerhood M, Nuzzo P, Kolodner K: A randomized trial of employment-based reinforcement of cocaine abstinence in injection drug users. J Appl Behav Anal. 2007, 40 (3): 387-410. 10.1901/jaba.2007.40-387.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Weatherby NR NL, Cesari H, Booth R, McCoy CB, Watters JK, Williams M, Chitwood DD: Validity of self-reported drug use among injection drug users and crack cocaine users recruited through street outreach. Eval Program Plann. 1994, 17 (4): 347-355. 10.1016/0149-7189(94)90035-3.View ArticleGoogle Scholar
  43. Darke S: Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998, 51 (3): 253-263. 10.1016/S0376-8716(98)00028-3. discussion 267–258View ArticlePubMedGoogle Scholar
  44. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2458/14/1153/prepub

Copyright

© Hayden et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement